IL23A and psoriasis: Subsequently, anti-IL23p19 inhibitors have been developed, and antibody therapies are now licensed for the treatment of CD, UC, and psoriasis with ongoing trials for further autoinflammatory conditions (Chyuan and Lai, 2020).